Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities

Internal Medicine Journal

Volumn 43, Issue 6, 2013, Pages 678-684

  Stamp, L K ^a   Wells, J E ^a   Pitama, S ^a   Faatoese, A ^a   Doughty, R N ^b   Whalley, G ^c   Richards, A M ^a   Cameron, V A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNITEC INSTITUTE OF TECHNOLOGY   (New Zealand)

Author keywords

Cardiovascular risk; Gout; Hyperuricaemia; Prevalence

Indexed keywords

ALLOPURINOL; GLUCOSE; HEMOGLOBIN A1C; LIPID; PROBENECID; URATE;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; GOUT; HEART DISEASE; HUMAN; HYPERTENSION; HYPERURICEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC SYNDROME X; NEW ZEALAND; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RURAL AREA; URBAN AREA;

ADULT; COHORT STUDIES; FEMALE; GOUT; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; NEW ZEALAND; OCEANIC ANCESTRY GROUP; RURAL POPULATION; URBAN POPULATION; YOUNG ADULT;

EID: 84879029589     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12062     Document Type: Article

References (29)

1. Kim K, Schumacher HR, Hunsche E, Wertheimer A, Kong S. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003; 25: 1593-1617.
2. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P etal. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324.
3. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J etal. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007; 46: 1372-1374.
4. Klemp P, Stansfield S, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-26.
5. Winnard D, Wright C, Taylor W, Jackson G, Te Karu L, Gow P etal. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 2012; 51: 901-909.
6. Choi H, Ford E. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-447.
7. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health And Nutrition Examination Survey. JAMA 2002; 287: 356-359.
8. Hjortnaes J, Algra A, Olijhoek J, Huisman M, Jacobs J, van der Graaf Y etal. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 2007; 334: 1882-1887.
9. Mottillo S, Filion K, Genest J, Joseph L, Pilote L, Poirier P etal. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
10. Krishnan E, Baker J, Furst D, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54: 2688-2696.
11. Choi H, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
12. Baker J, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments and where do they leave us? Am J Med 2005; 118: 816-826.
13. Colvine K, Kerr A, McLachklan A, Gow P, Kumar S, Ly J etal. Cardiovascular disease risk factor assessment and management in gout; an alaysis using guideline-based electronic clinical decision support. N Z Med J 2008; 121: 73-81.
14. Pitama S, Wells J, Faatoese A, Tikao-Mason K, Robertson P, Hurla T etal. A Kaupapa Maori approach to a community cohort study of heart disease in New Zealand. Aust N Z J Public Health 2011; 35: 249-255.
15. Faatoese A, Pitama S, Gillies T, Robertson P, Huria T, Tikao-Mason K etal. Community screening for cardiovascular risk factors and levels of treatment in a rural Māori cohort. Aust N Z J Public Health 2011; 35: 517-523.
16. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8: 551-561.
17. Wells J. Making good use of numerical predictors: alternatives to categories or straight lines. Int J Methods Psychiatr Res 1998; 7: 66-71.
18. Cameron V, Faatoese A, Gillies M, Robertson P, Huria T, Doughty R etal. A cohort study comparing cardiovascular risk factors in rural Maori, urban Maori and non-Maori communities in New Zealand. BMJ Open 2012; 2: e000799.
19. Lennane G, Rose B, Isdale I. Gout in the Maori. Ann Rhem Dis. 1960; 19: 120-125.
20. Prior I, Rose B. Uric acid, gout and public health in the South Pacific. N Z Med J 1966; 65: 295-300.
21. Campion E, Glynn R, DeLabry L. Asymptomatic hyperuricaemia: risks and consequence in the normative aging study. Am J Med 1987; 82: 421-426.
22. Norman A, Ang D, Ogston S, Lang C, Struthers A. Effect of high dose allopurinol on exercise in patients withy chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375: 2161-2167.
23. Rentoukas E, Tasarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 2010; 145: 257-258.
24. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N etal. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal function. Int Urol Nephrol 2007; 39: 1227-1233.
25. Chuang S, Lee S, Hsieh Y, Pan W. Trends in hyperuricaemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr 2011; 20: 301-308.
26. Stamp L, Zhu X, Dalbeth N, Jordan S, Edwards N, Taylor W. Serum urate as a soluble biomarker in chronic gout - evidence that serum urate fulfils the OMERACT validation criteria for soluble biomarkers. Semin Arthritis Rheum 2011; 40: 483-500.
27. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010; 12: R223.
28. Wallace S, Robinson H, Masi A, Decker J, McCarty D, Yu T. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
29. McAdams M, Maynard J, Baer A, Kottgen A, Clipp S, Coresh J etal. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol 2011; 38: 135-141.